Table 4.
Adverse effects of remifentanil: Experiment 1a
| SC T1 |
OS T1 |
SC T2 |
OS T2 |
|||||
|---|---|---|---|---|---|---|---|---|
| Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | |
| Headache | 1.38 | 0.13 | 1.06 | 0.06 | 1.19 | 0.10 | 1.06 | 0.06 |
| Dizziness | 1.00 | 0 | 1.00 | 0 | 1.00 | 0 | 1.00 | 0 |
| Nausea | 1.00 | 0 | 1.00 | 0 | 1.06 | 0.06 | 1.06 | 0.06 |
| Sedation | 1.44 | 0.13 | 1.13 | 0.09 | 1.44 | 0.24 | 1.38 | 0.18 |
| Blurred vision | 1.00 | 0 | 1.00 | 0 | 1.00 | 0 | 1.00 | 0 |
| Dry skin | 1.00 | 0 | 1.00 | 0 | 1.13 | 0.09 | 1.00 | 0 |
| Dry mouth | 1.00 | 0 | 1.00 | 0 | 1.25 | 0.11 | 1.00 | 0 |
| SC T3 |
OS T3 |
SC T4 |
OS T4 |
|||||
|---|---|---|---|---|---|---|---|---|
| Mean | SEM | Mean | SEM | Mean | SEM | Mean | SEM | |
| Headache | 1.06 | 0.06 | 1.06 | 0.06 | 1.06 | 0.06 | 1.06 | 0.06 |
| Dizziness | 1.06 | 0.06 | 1.00 | 0 | 1.13 | 0.09 | 1.13 | 0.09 |
| Nausea | 1.00 | 0 | 1.00 | 0 | 1.13 | 0.09 | 1.06 | 0.06 |
| Sedation | 1.75 | 0.31 | 1.50 | 0.20 | 1.75 | 0.21 | 2.00 | 0.39 |
| Blurred vision | 1.19 | 0.10 | 1.13 | 0.09 | 1.00 | 0 | 1.00 | 0 |
| Dry skin | 1.06 | 0.06 | 1.00 | 0 | 1.25 | 0.11 | 1.19 | 0.10 |
| Dry mouth | 1.00 | 0 | 1.00 | 0 | 1.13 | 0.09 | 2.56 | 1.30 |
aBefore and after each session, subjects also answered a 7 item questionnaire regarding adverse effects. Each adverse effect could be rated as “inexistent,” “very weak,” “weak,” “moderate,” “strong,” “very strong,” and “extremely strong” (scores 1–7). SC, Saline control group; OS, opioid suspension group; T1, before Session 1; T2, after Session 1; T3, before Session 2; T4, after Session 2.